​

Nektar Therapeutics Ownership | Who Owns Nektar Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Nektar Therapeutics Ownership Summary

Nektar Therapeutics is owned by 130.25% institutional investors, 0.45% insiders. Fmr is the largest institutional shareholder, holding 21.20% of NKTR shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 5.52% of its assets in Nektar Therapeutics shares.

NKTR Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockNektar Therapeutics130.25%0.45%-30.69%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr4.30M21.20%$309.61M
Bvf inc/il2.56M12.61%$184.16M
Two seas capital lp1.96M9.65%$140.96M
Blackrock15.16M7.78%$18.79M
Vanguard group1.03M7.29%$43.43M
Two sigma investments, lp930.74K4.59%$66.97M
Prosight management, lp735.00K3.62%$52.88M
Blackrock funding, inc. /de692.65K3.41%$49.84M
Morgan stanley659.39K3.25%$47.44M
Armistice capital578.00K2.85%$41.59M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
22nw, lp281.12K13.86%$20.23M
Prosight management, lp735.00K8.67%$52.88M
Bvf inc/il2.56M5.87%$184.16M
Great point partners316.45K5.23%$22.77M
Act capital management70.90K4.01%$5.10M
Monashee investment management100.00K3.91%$7.20M
Superstring capital management lp51.27K2.87%$2.92M
Dafna capital management165.18K2.70%$11.88M
Patient square capital lp210.00K2.68%$15.11M
Stonepine capital management85.00K2.45%$6.12M

Top Buyers

HolderShares% AssetsChange
Blackrock15.16M0.00%9.28M
Fmr4.30M0.02%4.20M
Altium capital management lp3.00M0.79%2.99M
Two seas capital lp1.96M1.97%1.21M
Bvf inc/il2.56M5.87%1.00M

Top Sellers

HolderShares% AssetsChange
Samlyn capital---9.67M
Eventide asset management---6.65M
Almitas capital---4.61M
Exome asset management---2.23M
Lynx1 capital management lp---2.07M

New Positions

HolderShares% AssetsChangeValue
Lord, abbett405.08K0.10%405.08K$29.15M
Vestal point capital, lp285.00K0.57%285.00K$20.51M
Orbimed advisors275.00K0.39%275.00K$19.79M
Braidwell lp222.70K0.53%222.70K$16.02M
Patient square capital lp210.00K2.68%210.00K$15.11M

Sold Out

HolderChange
Srs capital advisors-2.00
Salomon & ludwin-3.00
Clearstead advisors-5.00
Cornerstone planning group-5.00
Arlington trust-6.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202621415.05%26,436,04552.71%1300.86%14127.03%44-
Dec 31, 202568-57.23%5,169,695-64.12%360.35%44-59.26%14-48.15%
Sep 30, 202537-66.36%1,954,060-74.48%130.47%24-17.24%6-91.67%
Jun 30, 202537-77.30%2,048,084-98.35%140.42%10-86.49%27-44.90%
Mar 31, 20258-94.59%15,114,671-88.63%70.18%2-97.14%4-88.89%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S1.86M5.52%614.67K
Fidelity Growth Company Fund1.61M4.77%453.00K
Eventide Healthcare & Life Sciences I6.65M3.57%-
Vanguard US Total Market Shares ETF5.72M3.08%-
Vanguard Total Stock Mkt Idx Inv1.03M3.04%170.20K
iShares Russell 2000 ETF4.62M2.48%-
Fidelity Growth Company K6436.69K1.29%157.23K
Fidelity Series Growth Company391.61K1.16%83.00K
Vanguard Institutional Extnd Mkt Idx Tr355.43K1.05%42.46K
iShares Russell 2000 Value ETF1.66M0.89%-

Recent Insider Transactions

DateNameRoleActivityValue
May 19, 2026Zalevsky Jonathan Chief R&D OfficerSell$13.04K
May 19, 2026ROBIN HOWARD W President & CEOSell$29.09K
Feb 18, 2026Zalevsky Jonathan Chief R&D OfficerSell$13.14K
Feb 18, 2026ROBIN HOWARD W President & CEOSell$30.88K
Jan 20, 2026Zalevsky Jonathan Chief R&D OfficerSell$137.94K

Insider Transactions Trends

DateBuySell
2026 Q2-2
2026 Q1-3
2025 Q4-3
2025 Q3-20
2025 Q2-3

NKTR Ownership FAQ

Who Owns Nektar Therapeutics?

Nektar Therapeutics shareholders are primarily institutional investors at 130.25%, followed by 0.45% insiders and -30.70% retail investors. The average institutional ownership in Nektar Therapeutics's industry, Biotech Stocks , is 35.75%, which Nektar Therapeutics exceeds.

Who owns the most shares of Nektar Therapeutics?

Nektar Therapeutics’s largest shareholders are Fmr (4.3M shares, 21.20%), Bvf inc/il (2.56M shares, 12.61%), and Two seas capital lp (1.96M shares, 9.65%). Together, they hold 43.46% of Nektar Therapeutics’s total shares outstanding.

Does Blackrock own Nektar Therapeutics?

Yes, BlackRock owns 7.78% of Nektar Therapeutics, totaling 15.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 18.79M$. In the last quarter, BlackRock increased its holdings by 9.28M shares, a 157.82% change.

Who is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested?

22nw, lp is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested, with 13.86% of its assets in 281.12K Nektar Therapeutics shares, valued at 20.23M$.

Who is the top mutual fund holder of Nektar Therapeutics shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Nektar Therapeutics shares, with 5.52% of its total shares outstanding invested in 1.86M Nektar Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools